SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

42 41% 0% 20% 40% 60% 80% 100% Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 512 , 3% 8,620 , 50% 310 , 2% 7,794 , 45% 41,691 , 52% 37,829 , 48% 39 , 0% 3 , 0% • Since the launch of generic versions of Treximet ® , Treximet ® AG has retained strong market share • 3 generic competitors have entered the market in 2018, including Aurobindo (Feb 2018), Sun (Sept 2018) and Mylan (Sept 2018) • Mylan launched late September with a low WAC price and has been competing for smaller wholesalers • In Q3 2018 Treximet ® brand was MAC’d at both ESI and CVS (CVS still has a 25% rebate on Treximet ® brand) • Treximet ® TRx through PPD has begun to slow down Treximet ® AG Treximet ® Molecule TRx Q 4 2018 to date ( 1 ) Treximet ® Molecule TRx Through Q3 2018 (1) As of 11/16/2018. Treximet ® AG Market Share Treximet ® LOE Macoven Aurobindo Sun Mylan Authorized Generic Produces